Rapport Therapeutics (RAPP) CEO Ceesay Abraham Sells 2,210 Shares

What Happened Ceesay Abraham, CEO of Rapport Therapeutics (RAPP), sold a total of 2,210 shares in open-market transactions on September 23, 2026, generating aggregate proceeds of approximately $86,565. The reported line items were: 1,952 shares at a weighted average price of $39.05 ($76,230), 215 shares at a weighted average price of $39.86 ($8,570), and 43 shares at $41.05 ($1,765). These were sales (transaction code S), which are commonly routine dispositions rather than an indicator of company outlook.

Key Details

• Transaction date: September 23, 2026; Form 4 filed September 24, 2026 (timely filing).
• Total shares sold: 2,210; total reported proceeds: ~$86,565.
• Prices reported: weighted averages of $39.05, $39.86, and $41.05. Footnotes indicate the larger blocks were executed across multiple trades at price ranges of $38.54–$39.48 and $39.57–$40.25, respectively; the filer can provide per-trade breakdown on request.
• Footnote: All transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted March 27, 2026.
• Shares owned after the transactions: not specified in the information provided.

Context

• These sales were executed under a pre-established 10b5‑1 plan, which often schedules trades to avoid trading on material nonpublic information and can reflect routine liquidity needs rather than a change in insider sentiment.
• Transaction code S = Sale. No options exercises, gifts, or awards were reported in this filing.